| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695554 | Gynecologic Oncology | 2017 | 6 Pages |
Abstract
Irinotecan and bevacizumab has activity in heavily pre-treated patients with recurrent ovarian cancer, including those with prior bevacizumab and topoisomerase inhibitor use.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Fernanda Musa, Bhavana Pothuri, Stephanie V. Blank, Huichung T. Ling, James L. Speyer, John Curtin, Leslie Boyd, Xiaochun Li, Judith D. Goldberg, Franco Muggia, Amy Tiersten,